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H-Y Antibody Results in Male Patients with Female Donors
Any H-Y
Antibody
2 or more H-Y
Antibodies
TCD HSCT  prophylactic CD8 depleted DLI 6/6 100% 4/6 67%
TCD HSCT alone 3/9 33% 1/9 11%
CD8 depleted DLI for relapse 9/12 75% 9/12 75%
Unmanipulated DLI for relapse 8/12 67% 2/12 17%
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IN VIVO TRAFFICKING OF CD4CD25 REGULATORY T-CELLS IN
ALLOGENEIC RECIPIENTS USING BIOLUMINESCENCE IMAGING
Nguyen, V.H.; Wieland, C.; Contag, C.; Negrin, R. Stanford University
School of Medicine, Stanford, CA.
CD4CD25 regulatory T-cells (Treg) have the potential to
suppress aberrant immune responses and to regulate peripheral
T-cell homeostasis. In a murine allogeneic bone marrow transplan-
tation (BMT) model, we previously showed that Treg suppress
graft-versus-host-disease (GVHD) without abrogating the beneﬁ-
cial graft-versus-tumor immunological effect. In the current study,
we investigate the in vivo trafﬁcking of Treg to better understand
how localization may affect their regulatory function. We have
developed and characterized a transgenic mouse which constitu-
tively expresses the luciferase gene in all hematologic cells. Treg
from the spleen and lymph nodes of luc transgenic FVB/N
(H-2q) mice were cotransplanted into lethally-irradiated Balb/c
(H-2d) host along with wild-type FVB/N T-cell-depleted bone
marrow (TCD-BM) cells and whole splenocytes, the latter con-
taining approximately 30% T cells, which induce GVHD. Biolu-
minescence imaging (BLI) was performed at various time points.
Within the ﬁrst 48 hours, Treg localized to the cervical lymph
nodes (LN) and the spleen. By day 3, signal is detected in other LN
(axillary, mesenteric, inguinal) as well as Peyer’s patches and liver.
Signal intensity, measured by photons/second/mouse, signiﬁcantly
increased and peaked on day 4, consistent with the migration and
proliferation of Treg to and at these secondary lymphoid organs,
respectively. Skin inﬁltration of Treg is noted on day 6, congruent
with a decreased intensity in the spleen, liver, and lymph nodes. A
similar pattern of early migration and proliferation of effector
immune cells is noted in the GVHD control group, which is
transplanted with wild-type FVB/N TCD-BM and luc FVB/N
whole splenocytes. However, with the GVHD group, the signal
intensity continues to increase at all sites. Continued BLI of the
Treg group up to day 45 demonstrates persistent strong signal in
lymphoid organs and skin sites. Clinically, the Treg group had no
signiﬁcant evidence of GVHD. Chimerism studies on day 45 show
complete donor origin, however, lymphoid reconstitution of
CD4 and CD8 T cells is delayed in the GVHD control group
and enhanced in the recipients transplanted with Treg. The afore-
mentioned results indicate that in vivo, Treg proliferate and sur-
vive long-term. In addition, they colocalize with effector immune
cells to secondary lymphoid tissues to positively impact clinical
outcomes and lymphoid reconstitution following major MHC-
mismatched BMT.
HEMATOPOIESIS/MESENCHYMAL CELLS
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BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AUGMENT TIS-
SUE ENGINEERED ENTEROCYTES
Gandia, C.; Yu, H.; Santiago, S.; Coats, E.; Defaria, W.; Ruiz, P.;
Tzakis, A.; Kleiner, G.I. University of Miami School of Medicine,
Miami, FL.
Bone marrow-derived MSCs have been demonstrated to have
multipotential differentiating ability. Despite recent advances in in
vitro models, a reliable method of expansion and long-term main-
tenance of normal intestinal epithelial cells (IECs) is lacking. Most
of the limited data arise from studies based on T84 and Caco-2
colon carcinoma lines. We evaluated a novel protocol of isolation
and long-term culture of IEC from rodent enterocytes. The ability
of MSC to augment tissue engineered small bowel was evaluated.
Methods: Small intestine from neonatal DA rats (12 days old) was
harvested and digested using cold and warm solution of dispase/
collagenase. Primary culture cells in minimal media with high
glutamine were initiated. No growth factors were used. Conﬁrma-
tion of epithelial and endothelial cells in the primary culture was
veriﬁed by Immunohistochemical markers (cytokeratin 19, 5, and
8; anti-cytokeratin basal monoclonal antibody; MadCAM-1; and
antilaminin B2). Long-term cultures ( 100 days) were obtained.
Cytokine secretion panels were determined by BioPlex assay and
intestinal metabolites (citrulline, praline, glutamine, lactate) by
GC/mass spectroscopy. Bone marrow-derived MSCs were added
to cultures. Results: Primary culture tissue expressed intestinal
epithelial and endothelial. Cytokeratin 19 was the most abundant,
followed by cytokeratin 5 and 8, MadCAM-1, anticytokeratin
basal monoclonal antibody, and laminin B12 (in descending order).
Primary and long-term ( 100 days) cultures secreted citrulline, a
speciﬁc marker of functional enterocytes. Addition of bone mar-
row-derived MSCs signiﬁcantly augmented citrulline production
(P  .05). Cytokines TNF alpha, IL-10, and GMCSF correlated
with citrulline levels. The results suggest that bone marrow-de-
rived MSCs augment intestinal development in an in vitro rodent
model and may be useful in tissue engineering applications.
HISTOCOMPATIBILITY/ALTERNATIVE
STEM CELL SOURCES
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PARTICULAR HLA-DPB1 ALLELE MISMATCHES PREDICT FOR WORSE
OVERALL SURVIVAL IN RECIPIENTS OF UNRELATED DONOR HAEMA-
TOPOIETIC STEM CELL TRANSPLANTS
Shaw, B.E.; Marsh, S.G.E.; Mayor, N.P.; Madrigal, A. The Anthony
Nolan Research Institute, Royal Free Hospital, Hampstead, London,
United Kingdom.
In the HLA-DPB1 molecule there are 6 hypervariable regions
(HVR), A to F, in exon 2, which encode for the  domain and
form the peptide binding groove (PB). Within each of these HVRs
are 1 or more amino acids that are polymorphic, and this poly-
morphism is important in determining the peptides that will bind
the recognition by T-cell receptors or both. Mismatches at this
level may predict for transplant complications, and this analysis
may contribute to a better understanding of the function of DPB1.
We analyzed the outcome in 282 mixed transplant pairs who
received an hematopoietic stem cell transplant (HSCT) from an
unrelated donor. All of the pairs were matched at the allelic level
for class I and II. Transplant pairs were assessed as matched or
mismatched for HVRs A to F, in a graft-versus-host direction.
Mismatches at both amino acid position 65 (within HVRD) and 57
(within HVR C) were associated with transplant complications.
Position 65 was matched in 231 (82%) pairs and mismatched in 51
(18%). Matched pairs had a signiﬁcantly improved overall survival
(OS) compared with mismatched pairs (49% vs 35%; log rank P 
.039). Position 57 was matched in 233 pairs (83%) and mismatched
in 49 (17%). There was no signiﬁcant association between match-
ing at either position and graft-versus-host disease or disease re-
lapse. In contrast, mismatched pairs had a signiﬁcantly increased
rate of transplant-related mortality (TRM). In conclusion, we have
shown a signiﬁcantly worse OS, largely mediated by an increased
TRM, in recipients of HSCT from UD which are mismatched at
amino acid positions 57 and 65 of the DPB1 molecule.
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